TGIF: Comic relief

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.

Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.